List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7927399/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A systematic comparison of hepatobiliary adverse drug reactions in FDA and EMA drug labeling reveals discrepancies. Drug Discovery Today, 2022, 27, 337-346.	3.2	5
2	Petasites for Migraine Prevention: New Data on Mode of Action, Pharmacology and Safety. A Narrative Review. Frontiers in Neurology, 2022, 13, 864689.	1.1	2
3	miRNAs in lung cancer. A systematic review identifies predictive and prognostic miRNA candidates for precision medicine in lung cancer. Translational Research, 2021, 230, 164-196.	2.2	89
4	Advances in Liver Cancer Stem Cell Isolation and their Characterization. Stem Cell Reviews and Reports, 2021, 17, 1215-1238.	1.7	14
5	Reliable miRNA biomarker quantification in clinical practice – are we there yet?. Analytical Biochemistry, 2021, 634, 114431.	1.1	0
6	The landscape of hepatobiliary adverse reactions across 53 herbal and dietary supplements reveals immune-mediated injury as a common cause of hepatitis. Archives of Toxicology, 2020, 94, 273-293.	1.9	13
7	Cancer genomics predicts disease relapse and therapeutic response to neoadjuvant chemotherapy of hormone sensitive breast cancers. Scientific Reports, 2020, 10, 8188.	1.6	5
8	An adverse outcome pathway for immune-mediated and allergic hepatitis: a case study with the NSAID diclofenac. Archives of Toxicology, 2020, 94, 2733-2748.	1.9	8
9	Treatment of cyclosporine induced hypertension: Results from a long-term observational study using different antihypertensive medications. Vascular Pharmacology, 2019, 115, 69-83.	1.0	15
10	Hepatobiliary Events in Migraine Therapy with Herbs—The Case of Petadolex, A Petasites Hybridus Extract. Journal of Clinical Medicine, 2019, 8, 652.	1.0	16
11	ApoE is a major determinant of hepatic bile acid homeostasis in mice. Journal of Nutritional Biochemistry, 2018, 52, 82-91.	1.9	8
12	Nâ€acetylcysteine and prednisolone treatment improved serum biochemistries in suspected flupirtine cases of severe idiosyncratic liver injury. Liver International, 2018, 38, 365-376.	1.9	23
13	Genomics of lipid-laden human hepatocyte cultures enables drug target screening for the treatment of non-alcoholic fatty liver disease. BMC Medical Genomics, 2018, 11, 111.	0.7	24
14	The Development of a Database for Herbal and Dietary Supplement Induced Liver Toxicity. International Journal of Molecular Sciences, 2018, 19, 2955.	1.8	21
15	Serum proteome mapping of EGF transgenic mice reveal mechanistic biomarkers of lung cancer precursor lesions with clinical significance for human adenocarcinomas. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 3122-3144.	1.8	8
16	Primary nonâ€function is frequently associated with fatty liver allografts and high mortality after reâ€ŧransplantation. Liver International, 2017, 37, 1219-1228.	1.9	44
17	A unifying mathematical model of lipid droplet metabolism reveals key molecular players in the development of hepatic steatosis. FEBS Journal, 2017, 284, 3245-3261.	2.2	21
18	Associations of Drug Lipophilicity and Extent of Metabolism with Drug-Induced Liver Injury. International Journal of Molecular Sciences, 2017, 18, 1335.	1.8	53

#	Article	IF	CITATIONS
19	Drug-Induced Liver Injury. BioMed Research International, 2017, 2017, 1-2.	0.9	7
20	In vitro to in vivo extrapolation for drug-induced liver injury using a pair ranking method. ALTEX: Alternatives To Animal Experimentation, 2017, 34, 399-407.	0.9	35
21	The pathogenesis of diclofenac induced immunoallergic hepatitis in a canine model of liver injury. Oncotarget, 2017, 8, 107763-107824.	0.8	15
22	Oncogenomics of c-Myc transgenic mice reveal novel regulators of extracellular signaling, angiogenesis and invasion with clinical significance for human lung adenocarcinoma. Oncotarget, 2017, 8, 101808-101831.	0.8	16
23	Immunogenomics reveal molecular circuits of diclofenac induced liver injury in mice. Oncotarget, 2016, 7, 14983-15017.	0.8	15
24	A Model to predict severity of drugâ€induced liver injury in humans. Hepatology, 2016, 64, 931-940.	3.6	74
25	Regulation of glycosylphosphatidylinositol-anchored proteins and GPI-phospholipase D in a c-Myc transgenic mouse model of hepatocellular carcinoma and human HCC. Biological Chemistry, 2016, 397, 1147-1162.	1.2	3
26	Inhibition of bile salt transport by drugs associated with liver injury in primary hepatocytes from human, monkey, dog, rat, and mouse. Chemico-Biological Interactions, 2016, 255, 45-54.	1.7	33
27	Gene expression profiling of calcium-channel antagonists in the heart of hypertensive and normotensive rats reveals class specific effects. Vascular Pharmacology, 2016, 87, 121-128.	1.0	1
28	Mechanistically linked serum miRNAs distinguish between drug induced and fatty liver disease of different grades. Scientific Reports, 2016, 6, 23709.	1.6	29
29	Genomics of human fatty liver disease reveal mechanistically linked lipid droplet–associated gene regulations in bland steatosis and nonalcoholic steatohepatitis. Translational Research, 2016, 177, 41-69.	2.2	30
30	Evaluation of multiple mechanism-based toxicity endpoints in primary cultured human hepatocytes for the identification of drugs with clinical hepatotoxicity: Results from 152 marketed drugs with known liver injury profiles. Chemico-Biological Interactions, 2016, 255, 3-11.	1.7	37
31	c-Myc targeted regulators of cell metabolism in a transgenic mouse model of papillary lung adenocarcinoma. Oncotarget, 2016, 7, 65514-65539.	0.8	19
32	Immune-mediated liver injury of the cancer therapeutic antibody catumaxomab targeting EpCAM, CD3 and Fcl ³ receptors. Oncotarget, 2016, 7, 28059-28074.	0.8	56
33	Drug-induced liver injury: Interactions between drug properties and host factors. Journal of Hepatology, 2015, 63, 503-514.	1.8	319
34	Proteome mapping of epidermal growth factor induced hepatocellular carcinomas identifies novel cell metabolism targets and mitogen activated protein kinase signalling events. BMC Genomics, 2015, 16, 124.	1.2	9
35	Metabolic activation and analgesic effect of flupirtine in healthy subjects, influence of the polymorphic NAT2, <scp>UGT1A1</scp> and GSTP1. British Journal of Clinical Pharmacology, 2015, 79, 501-513.	1.1	26
36	Regulation of Liver Enriched Transcription Factors in Rat Hepatocytes Cultures on Collagen and EHS Sarcoma Matrices. PLoS ONE, 2015, 10, e0124867.	1.1	14

#	Article	IF	CITATIONS
37	Decoding c-Myc networks of cell cycle and apoptosis regulated genes in a transgenic mouse model of papillary lung adenocarcinomas. Oncotarget, 2015, 6, 31569-31592.	0.8	26
38	Whole Genome Transcript Profiling of Drug Induced Steatosis in Rats Reveals a Gene Signature Predictive of Outcome. PLoS ONE, 2014, 9, e114085.	1.1	48
39	Explanted Diseased Livers – A Possible Source of Metabolic Competent Primary Human Hepatocytes. PLoS ONE, 2014, 9, e101386.	1.1	55
40	Deciphering miRNA transcription factor feed-forward loops to identify drug repurposing candidates for cystic fibrosis. Genome Medicine, 2014, 6, 94.	3.6	27
41	Recent insights into the molecular pathophysiology of lipid droplet formation in hepatocytes. Progress in Lipid Research, 2014, 54, 86-112.	5.3	95
42	How useful are clinical liver function tests in in vitro human hepatotoxicity assays?. Toxicology in Vitro, 2014, 28, 784-795.	1.1	31
43	A rat toxicogenomics study with the calcium sensitizer EMD82571 reveals a pleiotropic cause of teratogenicity. Reproductive Toxicology, 2014, 47, 89-101.	1.3	1
44	Recent advances in live cell imaging of hepatoma cells. BMC Cell Biology, 2014, 15, 26.	3.0	11
45	Isolation and cultivation of metabolically competent alveolar epithelial cells from A/J mice. Toxicology in Vitro, 2014, 28, 812-821.	1.1	4
46	A Unifying Ontology to Integrate Histological and Clinical Observations for Drug-Induced Liver Injury. American Journal of Pathology, 2013, 182, 1180-1187.	1.9	23
47	Serum acute phase reactants hallmark healthy individuals at risk for acetaminophen-induced liver injury. Genome Medicine, 2013, 5, 86.	3.6	29
48	High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology, 2013, 58, 388-396.	3.6	288
49	A Cross-Platform Comparison of Affymetrix and Agilent Microarrays Reveals Discordant miRNA Expression in Lung Tumors of c-Raf Transgenic Mice. PLoS ONE, 2013, 8, e78870.	1.1	43
50	Transcriptional Defect of an Inherited NKX2-5 Haplotype Comprising a SNP, a Nonsynonymous and a Synonymous Mutation, Associated with Human Congenital Heart Disease. PLoS ONE, 2013, 8, e83295.	1.1	31
51	MYCâ€regulated genes involved in liver cell dysplasia identified in a transgenic model of liver cancer. Journal of Pathology, 2012, 228, 520-533.	2.1	31
52	PET/CT Imaging of c-Myc Transgenic Mice Identifies the Genotoxic N-Nitroso-Diethylamine as Carcinogen in a Short-Term Cancer Bioassay. PLoS ONE, 2012, 7, e30432.	1.1	7
53	A Cross-Platform Comparison of Genome-Wide Expression Changes of Laser Microdissected Lung Tissue of C-Raf Transgenic Mice Using 3′IVT and Exon Array. PLoS ONE, 2012, 7, e40778.	1.1	5
54	A Rapid Screening Assay to Search for Phosphorylated Proteins in Tissue Extracts. PLoS ONE, 2012, 7, e50025.	1.1	1

#	Article	IF	CITATIONS
55	Combined Serum and Tissue Proteomic Study Applied to a c-Myc Transgenic Mouse Model of Hepatocellular Carcinoma Identified Novel Disease Regulated Proteins Suitable for Diagnosis and Therapeutic Intervention Strategies. Journal of Proteome Research, 2011, 10, 3012-3030.	1.8	14
56	Advanced Computational Biology Methods Identify Molecular Switches for Malignancy in an EGF Mouse Model of Liver Cancer. PLoS ONE, 2011, 6, e17738.	1.1	17
57	Correlation versus Causation? Pharmacovigilance of the Analgesic Flupirtine Exemplifies the Need for Refined Spontaneous ADR Reporting. PLoS ONE, 2011, 6, e25221.	1.1	36
58	Pathology of flupirtine-induced liver injury:. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 458, 709-716.	1.4	37
59	HNF4alpha Dysfunction as a Molecular Rational for Cyclosporine Induced Hypertension. PLoS ONE, 2011, 6, e16319.	1.1	13
60	HNF4alpha and HNF1alpha Dysfunction as a Molecular Rational for Cyclosporine Induced Posttransplantation Diabetes Mellitus. PLoS ONE, 2009, 4, e4662.	1.1	13
61	Molecular Characterization of Lung Dysplasia Induced by c-Raf-1. PLoS ONE, 2009, 4, e5637.	1.1	13
62	Toxicogenomics Applied to Cultures of Human Hepatocytes Enabled an Identification of Novel Petasites hybridus Extracts for the Treatment of Migraine with Improved Hepatobiliary Safety. Toxicological Sciences, 2009, 112, 507-520.	1.4	21
63	A 2-DE MALDI-TOF study to identify disease regulated serum proteins in lung cancer of c-myc transgenic mice. Proteomics, 2009, 9, 1044-1056.	1.3	28
64	Genderâ€incompatible liver transplantation is not a risk factor for patient survival. Liver International, 2009, 29, 196-202.	1.9	13
65	Cancer Genomics Identifies Regulatory Gene Networks Associated with the Transition from Dysplasia to Advanced Lung Adenocarcinomas Induced by c-Raf-1. PLoS ONE, 2009, 4, e7315.	1.1	33
66	Detection of early signals of hepatotoxicity by gene expression profiling studies with cultures of metabolically competent human hepatocytes. Archives of Toxicology, 2008, 82, 89-101.	1.9	27
67	Quantitative mass spectrometry to investigate epidermal growth factor receptor phosphorylation dynamics. Mass Spectrometry Reviews, 2008, 27, 51-65.	2.8	15
68	Mapping of the Serum Proteome of Hepatocellular Carcinoma Induced by Targeted Overexpression of Epidermal Growth Factor to Liver Cells of Transgenic Mice. Journal of Proteome Research, 2008, 7, 928-937.	1.8	7
69	EPS15R, TASP1, and PRPF3 Are Novel Disease Candidate Genes Targeted by HNF4α Splice Variants in Hepatocellular Carcinomas. Gastroenterology, 2008, 134, 1191-1202.	0.6	30
70	Molecular Mechanisms and Therapeutic Targets in Steatosis and Steatohepatitis. Pharmacological Reviews, 2008, 60, 311-357.	7.1	346
71	Serum proteomics of lung adenocarcinomas induced by targeted overexpression of câ€raf in alveolar epithelium identifies candidate biomarkers. Proteomics, 2007, 7, 3980-3991.	1.3	33
72	Drug-induced phospholipidosis, FEBS Letters, 2006, 580, 5533-5540.	1.3	283

#	Article	IF	CITATIONS
73	Primary rat alveolar epithelial cells for use in biotransformation and toxicity studies. Toxicology in Vitro, 2006, 20, 757-766.	1.1	7
74	Nifedipine represses ion channels, transporters and Ca2+-binding proteins in hearts of spontaneously hypertensive rats. Toxicology and Applied Pharmacology, 2006, 213, 224-234.	1.3	7
75	Expression of Xenobiotic Metabolizing Enzymes in Different Lung Compartments of Smokers and Nonsmokers. Environmental Health Perspectives, 2006, 114, 1655-1661.	2.8	107
76	Epidermal growth factor-induced hepatocellular carcinoma: gene expression profiles in precursor lesions, early stage and solitary tumours. Oncogene, 2005, 24, 1809-1819.	2.6	106
77	METABOLISM OF VERAPAMIL IN CULTURES OF RAT ALVEOLAR EPITHELIAL CELLS AND PHARMACOKINETICS AFTER ADMINISTRATION BY INTRAVENOUS AND INHALATION ROUTES. Drug Metabolism and Disposition, 2005, 33, 1108-1114.	1.7	10
78	Liver-Enriched Transcription Factors in Liver Function and Development. Part II: the C/EBPs and D Site-Binding Protein in Cell Cycle Control, Carcinogenesis, Circadian Gene Regulation, Liver Regeneration, Apoptosis, and Liver-Specific Gene Regulation. Pharmacological Reviews, 2004, 56, 291-330.	7.1	205
79	DNA adducts in cultures of polychlorinated biphenyl-treated human hepatocytes. Toxicology and Applied Pharmacology, 2003, 188, 81-91.	1.3	31
80	Liver-Enriched Transcription Factors in Liver Function and Development. Part I: The Hepatocyte Nuclear Factor Network and Liver-Specific Gene Expression. Pharmacological Reviews, 2002, 54, 129-158.	7.1	256
81	Application of restricted access material (RAM) with precolumn-switching and matrix solid-phase dispersion (MSPD) to the study of the metabolism and pharmacokinetics of Verapamil. Analytical and Bioanalytical Chemistry, 2002, 374, 1179-1186.	1.9	20
82	Aroclor 1254 Modulates Gene Expression of Nuclear Transcription Factors: Implications for Albumin Gene Transcription and Protein Synthesis in Rat Hepatocyte Cultures. Toxicology and Applied Pharmacology, 2002, 181, 79-88.	1.3	23